5-Aryl-3-(alkylthio)-4H-1,2,4-triazoles as selective antagonists of strychnine-induced convulsions and potential antispastic agents. 1994

J M Kane, and M A Staeger, and C R Dalton, and F P Miller, and M W Dudley, and A M Ogden, and J H Kehne, and H J Ketteler, and T C McCloskey, and Y Senyah
Marion Merrell Dow Research Institute, Cincinnati, Ohio 45215.

Selected examples from three series of isomeric (alkylthio)-1,2,4-triazoles were prepared and examined for anticonvulsant activity versus strychnine-, maximal-electroshock-, pentylenetetrazole-, and 3-mercaptopropionic-acid-induced seizures in mice. A number of 5-aryl-3-(alkylthio)-4H-1,2,4-triazoles were selective antagonists of strychnine-induced convulsions. The isomeric 3-aryl-5-(alkylthio)- and 5-aryl-3-(alkylthio)-1H-1,2,4-triazoles were essentially inactive as anticonvulsants. The most potent antagonist of strychnine-induced convulsions was 5-(2-fluorophenyl)-4-methyl-3-(methylthio)-4H-1,2,4-triazole (3s), while the most selective antagonist was 5-(3-fluorophenyl)-4-methyl-3-(methylsulfonyl)-4H-1,2,4-triazole (3aa). The anticonvulsant profiles of these 4H-1,2,4-triazoles suggested that they were acting functionally like glycine receptor agonists. Since it has recently been postulated that compounds possessing glycine-agonist-like properties might be useful in the treatment of spasticity, we examined 5-phenyl-4-methyl-3-(methylsulfonyl)-4H-1,2,4-triazole (3c) in an in vivo model of spasticity. In this regard, 3c reduced the occurrence of hyperreflexia in rats that had received spinal transections 5-10 weeks previously. While triazole 3c appeared to possess glycine-agonist-like properties in vivo, it did not displace [3H]strychnine binding from rat brain stem/spinal cord membranes in vitro. On the other hand, 3c enhanced muscimol-stimulated 36Cl influx in a rat cerebellar membrane preparation, indicating a possible interaction of these triazoles with the GABAA receptor.

UI MeSH Term Description Entries
D008297 Male Males
D009128 Muscle Spasticity A form of muscle hypertonia associated with upper MOTOR NEURON DISEASE. Resistance to passive stretch of a spastic muscle results in minimal initial resistance (a "free interval") followed by an incremental increase in muscle tone. Tone increases in proportion to the velocity of stretch. Spasticity is usually accompanied by HYPERREFLEXIA and variable degrees of MUSCLE WEAKNESS. (From Adams et al., Principles of Neurology, 6th ed, p54) Clasp-Knife Spasticity,Spastic,Clasp Knife Spasticity,Spasticity, Clasp-Knife,Spasticity, Muscle
D010243 Paralysis A general term most often used to describe severe or complete loss of muscle strength due to motor system disease from the level of the cerebral cortex to the muscle fiber. This term may also occasionally refer to a loss of sensory function. (From Adams et al., Principles of Neurology, 6th ed, p45) Palsy,Plegia,Todd Paralysis,Todd's Paralysis,Palsies,Paralyses,Paralysis, Todd,Paralysis, Todd's,Plegias,Todds Paralysis
D002531 Cerebellum The part of brain that lies behind the BRAIN STEM in the posterior base of skull (CRANIAL FOSSA, POSTERIOR). It is also known as the "little brain" with convolutions similar to those of CEREBRAL CORTEX, inner white matter, and deep cerebellar nuclei. Its function is to coordinate voluntary movements, maintain balance, and learn motor skills. Cerebella,Corpus Cerebelli,Parencephalon,Cerebellums,Parencephalons
D002540 Cerebral Cortex The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulci. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions. Allocortex,Archipallium,Cortex Cerebri,Cortical Plate,Paleocortex,Periallocortex,Allocortices,Archipalliums,Cerebral Cortices,Cortex Cerebrus,Cortex, Cerebral,Cortical Plates,Paleocortices,Periallocortices,Plate, Cortical
D002712 Chlorides Inorganic compounds derived from hydrochloric acid that contain the Cl- ion. Chloride,Chloride Ion Level,Ion Level, Chloride,Level, Chloride Ion
D004597 Electroshock Induction of a stress reaction in experimental subjects by means of an electrical shock; applies to either convulsive or non-convulsive states. Electroconvulsive Shock,Electroconvulsive Shocks,Electroshocks,Shock, Electroconvulsive,Shocks, Electroconvulsive
D005442 Flumazenil A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses. Flumazepil,Anexate,Lanexat,Ro 15-1788,Romazicon,Ro 15 1788,Ro 151788
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic

Related Publications

J M Kane, and M A Staeger, and C R Dalton, and F P Miller, and M W Dudley, and A M Ogden, and J H Kehne, and H J Ketteler, and T C McCloskey, and Y Senyah
October 1989, Ceskoslovenska farmacie,
J M Kane, and M A Staeger, and C R Dalton, and F P Miller, and M W Dudley, and A M Ogden, and J H Kehne, and H J Ketteler, and T C McCloskey, and Y Senyah
April 2006, Bioorganic & medicinal chemistry,
J M Kane, and M A Staeger, and C R Dalton, and F P Miller, and M W Dudley, and A M Ogden, and J H Kehne, and H J Ketteler, and T C McCloskey, and Y Senyah
July 1970, Journal of medicinal chemistry,
J M Kane, and M A Staeger, and C R Dalton, and F P Miller, and M W Dudley, and A M Ogden, and J H Kehne, and H J Ketteler, and T C McCloskey, and Y Senyah
August 1989, Anti-cancer drug design,
J M Kane, and M A Staeger, and C R Dalton, and F P Miller, and M W Dudley, and A M Ogden, and J H Kehne, and H J Ketteler, and T C McCloskey, and Y Senyah
March 1978, Chemical & pharmaceutical bulletin,
J M Kane, and M A Staeger, and C R Dalton, and F P Miller, and M W Dudley, and A M Ogden, and J H Kehne, and H J Ketteler, and T C McCloskey, and Y Senyah
July 1987, Il Farmaco; edizione scientifica,
J M Kane, and M A Staeger, and C R Dalton, and F P Miller, and M W Dudley, and A M Ogden, and J H Kehne, and H J Ketteler, and T C McCloskey, and Y Senyah
September 1982, Il Farmaco; edizione scientifica,
J M Kane, and M A Staeger, and C R Dalton, and F P Miller, and M W Dudley, and A M Ogden, and J H Kehne, and H J Ketteler, and T C McCloskey, and Y Senyah
December 1981, Il Farmaco; edizione scientifica,
J M Kane, and M A Staeger, and C R Dalton, and F P Miller, and M W Dudley, and A M Ogden, and J H Kehne, and H J Ketteler, and T C McCloskey, and Y Senyah
March 1993, Journal of medicinal chemistry,
J M Kane, and M A Staeger, and C R Dalton, and F P Miller, and M W Dudley, and A M Ogden, and J H Kehne, and H J Ketteler, and T C McCloskey, and Y Senyah
June 1972, Journal of medicinal chemistry,
Copied contents to your clipboard!